JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M512129200 on December 16, 2005

J. Biol. Chem., Vol. 281, Issue 8, 4887-4893, February 24, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/8/4887    most recent
M512129200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smal, C.
Right arrow Articles by Bontemps, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smal, C.
Right arrow Articles by Bontemps, F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Identification of in Vivo Phosphorylation Sites on Human Deoxycytidine Kinase

ROLE OF SER-74 IN THE CONTROL OF ENZYME ACTIVITY*

Caroline Smal{ddagger}1, Didier Vertommen§, Luc Bertrand§2, Sandrine Ntamashimikiro{ddagger}, Mark H. Rider§, Eric Van Den Neste{ddagger}||, and Françoise Bontemps{ddagger}3

From the {ddagger}Laboratory of Physiological Chemistry and §Hormone and Metabolic Research Unit, Christian de Duve Institute of Cellular Pathology, the Division of Cardiology and the ||Department of Hematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium

Deoxycytidine kinase (dCK) catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway in mammalian cells and plays a key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy. Although compelling evidence indicated that dCK activity might be regulated by phosphorylation/dephosphorylation, direct demonstration was lacking. Here we showed that dCK overexpressed in HEK 293T cells was labeled after incubating the cells with [32P]orthophosphate. Sorbitol, which was reported to decrease dCK activity, also decreased the labeling of dCK. These results indicated that dCK may exist as a phosphoprotein in vivo and that its activity can be correlated with its phosphorylation level. After purification of 32P-labeled dCK, digestion by trypsin, and analysis of the radioactive peptides by tandem mass spectrometry, the following four in vivo phosphorylation sites were identified: Thr-3, Ser-11, Ser-15, and Ser-74, the latter being the major phosphorylation site. Site-directed mutagenesis and use of an anti-phospho-Ser-74 antibody demonstrated that Ser-74 phosphorylation was crucial for dCK activity in HEK 293T cells, whereas phosphorylation of other identified sites did not seem essential. Phosphorylation of Ser-74 was also detected on endogenous dCK in leukemic cells, in which the Ser-74 phosphorylation state was increased by agents that enhanced dCK activity. Our study provided direct evidence that dCK activity can be controlled by phosphorylation in intact cells and highlights the importance of Ser-74 for dCK activity.


Received for publication, November 10, 2005 , and in revised form, December 16, 2005.

* This work was supported in part by grants from the Belgian Fonds National de la Recherche Scientifique (Télévie, FRSM, Crédit au Chercheur), the Interuniversity Attraction Poles Program-Belgian Science Policy (P5/05), The Bauchau Foundation, The Maisin Foundation, The Goor Foundation, and The Salus Sanguinis Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Télévie Fellow.

2 Research Associate of the Belgian Fonds National de la Recherche Scientifique.

3 To whom correspondence should be addressed: Laboratory of Physiological Chemistry, Christian de Duve Institute of Cellular Pathology, UCL-ICP 7539, 75 Av. Hippocrate, 1200 Brussels, Belgium. Tel.: 32-2-7647539; Fax: 32-2-7647598; E-mail: bontemps{at}bchm.ucl.ac.be.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. K. Lamba, K. Crews, S. Pounds, E. G. Schuetz, J. Gresham, V. Gandhi, W. Plunkett, J. Rubnitz, and R. Ribeiro
Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 935 - 945.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. Uga, C. Kuramori, A. Ohta, Y. Tsuboi, H. Tanaka, M. Hatakeyama, Y. Yamaguchi, T. Takahashi, M. Kizaki, and H. Handa
A New Mechanism of Methotrexate Action Revealed by Target Screening with Affinity Beads
Mol. Pharmacol., November 1, 2006; 70(5): 1832 - 1839.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.